Skip to main content

Actuate Therapeutics, Inc.

corporate_fare Company Profile

Actuate Therapeutics, Inc.

ACTU·NASDAQ·Life Sciences·CIK 0001652935

The company is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. It achieves this through the inhibition of glycogen synthase kinase-3 ("GSK-3"). The company's primary product in development is elraglusib, an ATP-competitive small molecule designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3β"). This enzyme is a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which contribute to tumor cell survival, growth, migration, and invasion. The company believes that blocking GSK-3β signaling ultimately leads to the death of cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and elraglusib is considered one of the most advanced GSK-3β inhibitors in clinical development. Elraglusib was previously known as 9-ING-41 but received the elraglusib International Nonproprietary Names ("INN") and United States Adopted Names ("USAN") generic name in 2021. The company has exclusively licensed elraglusib, which is a proprietary and patent-protected GSK-3 inhibitor developed through a collaboration between The Board of Trustees of the University of Illinois-Chicago ("UIC") and Northwestern University ("NU"). Elraglusib is believed to have broad therapeutic potential, with evidence of preclinical and clinical activity observed in various cancer types, including pancreatic, metastatic melanoma, lung, colon, breast, renal, and ovarian cancer, leukemias and lymphomas, as well as pediatric cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ACTU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ACTU spans 10-Q, 8-K, 424B5, S-1/A.

Recent high-impact activity:

  • Actuate Beats on Q3 Loss Per Share but Cash Falls to $2.1M With Going-Concern Doubt
  • Actuate Q3 10-Q: $2.1M Cash, Going-Concern Doubt, Over-Allotment Adds $1.5M
  • Actuate Gets Nasdaq Bid-Price Notice, 180 Days to Reach $1.00
  • Actuate Closes $11.0M Offering, Nets $9.96M With 46.5M Dilutive Shares and Warrants
  • Actuate Finalizes $11.0M Offering: 30.99M Shares Plus 15.49M Warrants at $0.71

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$22.23M
Diluted EPS
-$1.06
Op. Cash Flow
-$19.21M
Operating Income
-$22.5M
Cash & Equivalents
$13.16M
Debt / Equity
0.00×
Shares Outstanding
23.25M sh
Source: 10-K · filed 2026-03-26 · accession 0001683168-26-002257

Short Interest & Short Volume

2.12 days to cover

FINRA reported short interest of 1,298,553 shares in ACTU as of the October 30, 2026 settlement, a 30.5% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 44.4% of ACTU volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,298,553 shares as of October 30, 2026
Change vs prior period▼ 30.5%
Days to cover2.12 at avg daily volume of 611,422
Daily short volume (FINRA facilities)44.4% of 220,177 shares on November 20, 2026
5-day average short volume35.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ACTU, detected from its recent SEC filings · based on capital-structure filings through 2026-10-28.

1 recent capital raise1 shelf registration

Offering Priced at $0.71 Per Two Shares · Net Proceeds of $9.96 Million

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.2004 -11.05% today
52-week range · as of 2026-11-13 $0.2004 – $7.9
Market cap
$13.6M
Volume
646.6K (0.5× avg)
3-mo avg 1.3M
Live data · 2026-11-22 07:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACTU - Latest Insights

ACTU
Nov 13, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.2853
Real-time Price: $0.2004 info
Change: -$0.0849 (-30%) info
Market Cap: $13.604M info
ACTU
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2853
Real-time Price: $0.2004 info
Change: -$0.0849 (-30%) info
Market Cap: $13.604M info
ACTU
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3351
Real-time Price: $0.2004 info
Change: -$0.1347 (-40%) info
Market Cap: $13.604M info
ACTU
Oct 28, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3833
Real-time Price: $0.2004 info
Change: -$0.1829 (-48%) info
Market Cap: $13.604M info
ACTU
Oct 28, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.2004 info
Change: -$0.1696 (-46%) info
Market Cap: $13.604M info
ACTU
Oct 27, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.4279
Real-time Price: $0.2004 info
Change: -$0.2275 (-53%) info
Market Cap: $13.604M info
ACTU
Oct 19, 2026, 8:00 AM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.5805
Real-time Price: $0.2004 info
Change: -$0.3801 (-65%) info
Market Cap: $13.604M info
ACTU
Oct 14, 2026, 8:01 AM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $0.4748
Real-time Price: $0.2004 info
Change: -$0.2744 (-58%) info
Market Cap: $13.604M info
ACTU
Oct 08, 2026, 6:47 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $0.694
Real-time Price: $0.2004 info
Change: -$0.4936 (-71%) info
Market Cap: $13.604M info
ACTU
Oct 06, 2026, 4:52 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.8116
Real-time Price: $0.2004 info
Change: -$0.6112 (-75%) info
Market Cap: $13.604M info
ACTU
Aug 14, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.9901
Real-time Price: $0.2004 info
Change: -$0.7897 (-80%) info
Market Cap: $13.604M info
ACTU
Jul 17, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.44
Real-time Price: $0.2004 info
Change: -$1.24 (-86%) info
Market Cap: $13.604M info
ACTU
Jun 09, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $0.2004 info
Change: -$1.62 (-89%) info
Market Cap: $13.604M info
ACTU
Jun 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.04
Real-time Price: $0.2004 info
Change: -$1.84 (-90%) info
Market Cap: $13.604M info
ACTU
May 14, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $0.2004 info
Change: -$2.70 (-93%) info
Market Cap: $13.604M info
ACTU
May 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.90
Real-time Price: $0.2004 info
Change: -$2.70 (-93%) info
Market Cap: $13.604M info
ACTU
May 11, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $0.2004 info
Change: -$2.79 (-93%) info
Market Cap: $13.604M info
ACTU
May 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.47
Real-time Price: $0.2004 info
Change: -$3.27 (-94%) info
Market Cap: $13.604M info
ACTU
May 06, 2026, 10:15 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $0.2004 info
Change: -$2.79 (-93%) info
Market Cap: $13.604M info
ACTU
May 06, 2026, 9:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.01
Real-time Price: $0.2004 info
Change: -$2.81 (-93%) info
Market Cap: $13.604M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets